APUS: Apimeds Pharmaceuticals US Company Value to Net Income

Symbol and logo of brand Apimeds Pharmaceuticals, Inc. (APUS)

The price trajectory of Apimeds Pharmaceuticals (APUS) helps assess the risks associated with FDA approval and the outcomes of bee venom-based drug tests, where the metric stands at -0.10. Unique patents and complex certification cycles for bioccomponents serve as a moat for the business. The company is currently relying on existing capital reserves to fund R&D developments until full-scale market sales are launched.

Apimeds Pharmaceuticals, Inc. - APUS P/E Multiple (period 05/10/2025 - 11/12/2026)

Analytical breakdowns for Apimeds Pharmaceuticals

- price and consensus price forecast:
Stock Price Apimeds|APUS - Consensus Target
- market capitalization information:
Market Value Apimeds Pharmaceuticals US|APUS - Total Company Value
- balance sheet net asset value indicators:
Equity per Share Apimeds Pharmaceuticals|APUS - Book Capitalization|Market-to-Book Ratio apimedsus.com|APUS - Cumulative Company Assets
- company liabilities and liquidity data:
Total Debt to Capital Apimeds Pharmaceuticals|APUS - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Apimeds|APUS - Company Debts|Debts to Book Value Apimeds Pharmaceuticals US|APUS - Company Long-Term Debt|Company Short-Term Debt Apimeds Pharmaceuticals|Immediate Liquidity apimedsus.com
- financial results and valuation multiples details:
APUS - Net Profit|Projected Net Profit Apimeds Pharmaceuticals|APUS - Price to Earnings Ratio|Projected Price to Earnings Ratio Apimeds|APUS - PEG Multiple|EV/EBITDA Multiple Apimeds Pharmaceuticals US|APUS - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months Apimeds Pharmaceuticals|APUS - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months apimedsus.com|APUS - Earnings per share growth in current year|Expected earnings per share growth for next year Apimeds Pharmaceuticals
Comprehensive company analysis:APUS (apimedsus.com)
Core merchandise of Apimeds Pharmaceuticals

The investment profile of Apimeds Pharmaceuticals (APUS) is driven by the anticipation of FDA approval for bee venom-based drugs, making current R&D expenditures the primary driver of valuation. By analyzing the issuer's P/E ratio, an investor can see the relationship between market capitalization and net income, which allows for an assessment of the cost per dollar of earnings and determines the extent of the premium paid for the company's future success in clinical trials.

Analysis of competing companies

P/E Multiple jazzpharma.com|Price to Earnings Ratio CYTK (Cytokinetics, Incorporated)|PTCT (PTC Therapeutics Inc) - Company Value to Net Income|Price to Earnings Ratio Scholar Rock Corp SRRK|CNTA: Price to Earnings Multiple|Dyne Therapeutics, Inc. - P/E Multiple|Market Cap to Earnings edgewisetx.com|RAPP (Rapport Therapeutics) - Price to Earnings Ratio|Alumis Inc (ALMS) - P/E Multiple|Price to Earnings Ratio Kempharm|CTNM: Company Value to Net Income|Price to Earnings Ratio Larimar Therapeutics (LRMR)|CAPR - Market Cap to Earnings|Price to Earnings Ratio Entrada Therapeutics, Inc. TRDA|Channel Therapeutics Inc. - Price to Earnings Ratio|MNOV - Price to Earnings Ratio|Market Cap to Earnings Serina Pharma|BTAI: P/E Multiple|Market Cap to Net Income Ratio ProMIS Neurosciences, Inc. PMN|Price to Earnings Ratio AEON|Market Cap to Earnings NLS Pharma NLSP|P/E Multiple BNOX|P/E Multiple fsdpharma.com (HUGE)|Price to Earnings Ratio Reata Pharmaceuticals RETA